Lexeo Therapeutics (LXEO) Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $8.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 689.84% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 689.84% YoY) and the FY2025 annual result came in at $9.3 million, down 32.58% from the prior year.
• Accumulated Expenses retreated to $8.2 million in Q1 2026 per LXEO's latest filing, from $9.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $15.7 million in Q3 2024 and troughed at $1.0 million in Q1 2025.
• A 5-year average of $9.2 million and a median of $9.6 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 764.43% in 2024, then slumped 92.5% in 2025.
• Over 5 years, Accumulated Expenses stood at $6.4 million in 2022, then jumped by 68.85% to $10.8 million in 2023, then grew by 26.93% to $13.8 million in 2024, then tumbled by 32.58% to $9.3 million in 2025, then fell by 12.05% to $8.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $8.2 million, $9.3 million, and $9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.